Kush Arvind's most recent trade in Inhibikase Therapeutics Inc was a trade of 108,176 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc | Arvind Kush | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 108,176 | 108,176 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Arvind Kush | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 116,585 | 116,585 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Arvind Kush | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 56,600 | 56,600 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Arvind Kush | Director | Purchase of securities on an exchange or from another person at price $ 1.37 per share. | 21 Oct 2024 | 145,000 | 145,000 | - | 1.4 | 198,650 | Common Stock |
| Inhibikase Therapeutics Inc | Arvind Kush | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| RayzeBio Inc | Kush Arvind | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Feb 2024 | 301,745 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| RayzeBio Inc | Arvind Kush | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Feb 2024 | 164,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| RayzeBio Inc | Kush Arvind | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Feb 2024 | 149,777 | 0 | - | - | Employee Stock Option (right to buy) | |
| RayzeBio Inc | Kush Arvind | CHIEF FINANCIAL OFFICER | Sale or transfer of securities back to the company at price $ 62.50 per share. | 26 Feb 2024 | 78,433 | 0 | - | 62.5 | 4,902,063 | Common Stock |